The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $10.14 per share, indicating an increase of 0.5% compared to the year-ago period. Analysts forecast revenues of $3.19 billion, representing an increase of 0.8% year over year. The consensus EPS estimate for the quarter has been revised 2.5% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe. Prior t ...

TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of EYLEA® HD (aflibercept) Injection 8 mg. The presentations are part of 14 accepted abstracts on EYLEA HD and EYLEA® (aflibercept) Injection 2 mg that will be shared at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting from May 5 to 9 in Seattle. "Our extensive dat ...

Mammoth与Regeneron合作 - Mammoth与Regeneron宣布合作研究、开发和商业化体内CRISPR基因编辑疗法[1] - Mammoth将获得总额为1亿美元的前期付款和股权投资[1] - Regeneron正在开发利用抗体靶向的腺相关病毒载体(AAVs)来增强基因药物有效传递到特定组织和细胞类型[1] Mammoth的技术优势 - Mammoth正在开发新型超紧凑核酸酶和相关基因编辑系统，具有比其他CRISPR系统更小的尺寸[1] - Mammoth的超紧凑CRISPR系统解决了病毒传递的尺寸限制，并与Regeneron的靶向AAV技术相辅相成[2] - Mammoth的基因编辑系统和Regeneron的传递技术有望克服重大的传递障碍，有效到达全身各种组织，影响多种疾病[2] 商业化和发展 - Mammoth的编辑技术将获得广泛使用，Regeneron将领导开发和商业化[4]

Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss Additional presentations cover progress in novel genetic medicine delivery systems and immune response modulation TARRYTOWN, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that new and updated data across its genetic medicines portfolio will be presented at the American Society of Gene ...

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:REGN). The investigation concerns whether Regeneron and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On April 10, 2024, the U.S. Department of Justice ("DOJ") issued a press release announci ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Regeneron (REGN) , which belongs to the Zacks Medical - Biomedical and Genetics industry. This biopharmaceutical company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 10.51%. For the most recent quarter, Regeneron was expected to ...

Shares of Regeneron Pharmaceuticals (REGN) were down 1.70% on Apr 11, following a complaint filed by the U.S. Department of Justice against the company, alleging fraudulent drug pricing practices related to its lead drug, Eylea. The Department filed a complaint under the False Claims Act (FCA) against Regeneron, which manufactures and sells the ophthalmology drug, Eylea. The lawsuit was originally filed under the qui tam or whistleblower provisions of the FCA. Eylea is an anti-vascular endothelial growth fa ...

Key Takeaways Regeneron shares were lower ahead of the opening bell Thursday morning after the DOJ filed a complaint accusing the drugmaker of manipulating Medicare’s drug pricing process. The DOJ Alleges the company failed to report credit card fees that it paid distributors. Regeneron shares may find support around $915 from a nine-month trendline. A breakdown below this level could see a retest of a key horizontal line near $835. Shares in biotech giant Regeneron Pharmaceuticals (REGN) go under the micro ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and onl ...

Linvoseltamab关键试验数据 - Regeneron Pharmaceuticals, Inc.宣布了linvoseltamab在复发/难治性多发性骨髓瘤（MM）患者中的关键试验数据[1] - Linvoseltamab是一种正在研究的双特异性抗体，旨在连接多发性骨髓瘤细胞上的B细胞成熟抗原（BCMA）和表达CD3的T细胞，以促进T细胞激活和杀伤癌细胞[2] - Linvoseltamab治疗导致早期、持久且随时间加深的反应，对于这些经过重度治疗的患者群体来说，这些都是关键的疗效指标[3] - Linvoseltamab数据显示，117名患者中71%的客观反应率（ORR），46%的患者达到完全缓解（CR）或更好，62%的患者达到非常好的部分缓解（VGPR）或更好[4]